Please use this identifier to cite or link to this item:
http://cmuir.cmu.ac.th/jspui/handle/6653943832/75776
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chalaithorn Nantasupha | en_US |
dc.contributor.author | Chanisa Thonusin | en_US |
dc.contributor.author | Kittipat Charoenkwan | en_US |
dc.contributor.author | Siriporn Chattipakorn | en_US |
dc.contributor.author | Nipon Chattipakorn | en_US |
dc.date.accessioned | 2022-10-16T07:02:37Z | - |
dc.date.available | 2022-10-16T07:02:37Z | - |
dc.date.issued | 2021-01-01 | en_US |
dc.identifier.issn | 19438141 | en_US |
dc.identifier.other | 2-s2.0-85116325253 | en_US |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85116325253&origin=inward | en_US |
dc.identifier.uri | http://cmuir.cmu.ac.th/jspui/handle/6653943832/75776 | - |
dc.description.abstract | Cancer cells usually show adaptations to their metabolism that facilitate their growth, invasiveness, and metastasis. Therefore, reprogramming the energy metabolism is one of the current key foci of cancer research and treatment. Although aerobic glycolysis-the Warburg effect-has been thought to be the dominant energy metabolism in cancer, recent data indicate a different possibility, specifically that oxidative phosphorylation (OXPHOS) is the more likely form of energy metabolism in some cancer cells. Due to the heterogeneity of epithelial ovarian cancer, there are different metabolic preferences among cell types, study types (in vivo/in vitro), and invasiveness. Current knowledge acknowledges glycolysis to be the main energy provider in ovarian cancer growth, invasion, migration, and viability, so specific agents targeting the glycolysis or OXPHOS pathways have been used in previous studies to attenuate tumor progression and increase chemosensitization. However, chemoresistant cell lines exert various metabolic preferences. This review comprehensively summarizes the information from existing reports which could together provide an in-depth understanding and insights for the development of a novel targeted therapy which can be used as an adjunctive treatment to standard chemotherapy to decelerate tumor progression and decrease the epithelial ovarian cancer mortality rate. | en_US |
dc.subject | Biochemistry, Genetics and Molecular Biology | en_US |
dc.title | Metabolic reprogramming in epithelial ovarian cancer | en_US |
dc.type | Journal | en_US |
article.title.sourcetitle | American Journal of Translational Research | en_US |
article.volume | 13 | en_US |
article.stream.affiliations | Chiang Mai University | en_US |
Appears in Collections: | CMUL: Journal Articles |
Files in This Item:
There are no files associated with this item.
Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.